From Ascites to Malignant Peritoneal Mesothelioma: The Diagnostic Workup of a Rare Tumor

Cancer Diagnosis & Prognosis 2026 July 1 [Link] Mirko Nastasi, Chiara Ferrante, Giuliana Michelis, Enrica Branca, Manuel Ventura, Silvia Novello, Emanuela Laurita Abstract Background/aim: Ascites is a common clinical manifestation of a wide spectrum of heterogeneous underlying conditions. All possible causes of ascites should be considered in the differential diagnosis to ensure an appropriate diagnostic…

Read More

Conditional survival patterns and individualized prognostic prediction in malignant peritoneal mesothelioma

Scientific Reports 2026 June 1 [Link] Xiaofeng Liao, Chen Li, Ming Huang, Zheng Yao, Shikun Luo, Xiaoyu Lei Abstract Malignant peritoneal mesothelioma (MPM) is a rare, aggressive cancer with limited treatment options and extremely poor survival outcomes. Due to the disease’s low incidence, large-scale cohort studies to clarify survival outcomes and the impact of treatments…

Read More

FASN for diffuse malignant peritoneal mesothelioma: a prognostic biomarker after CRS+HIPEC and a therapeutic target

Journal of Translational Medicine 2026 May 21 [Link] Valentina Doldi, Chiara Maura Ciniselli, Claudia Aurelio, Enrica Favini, Silvio Marco Veronese, Fabio Bozzi, Shigeki Kusamura, Dario Baratti, Silvia Martini, Paolo Verderio, Marcello Deraco, Marco Folini, Paolo Gandellini, Sandro Pasquali, Nadia Zaffaroni Abstract Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and aggressive malignancy with limited…

Read More

The Diagnostic Value of Immunohistochemistry and Biomarkers in the Diagnosis of Mesothelioma in Pleural/Peritoneal Effusions

Diagnostic Cytopathology 2026 May 20 [Link] Suzanne M Selvaggi Abstract Background: Mesothelioma is a rare tumor that arises from the serosal cells lining the serous cavities, most commonly the pleura followed by the peritoneum. Presenting symptoms include pleuritic pain and bloody effusions that recur. Although cytologic analysis cannot determine the mesothelial subtype or in situ…

Read More

A case of diffuse malignant peritoneal mesothelioma: case report and literature review

Irish Journal of Medical Science 2026 May 19 [Link] Qian Zhao, Kangwei Xiong, Qiaoyun Wang, Lijiu Zhang Abstract Introduction: Diffuse malignant peritoneal mesothelioma (DMPM) is a very rare and life-threateningmalignant tumor. Case: We present a report of a rare case of a 70-year-old female patient with emaciation and poor appetite as manifestations. The characteristics of…

Read More

Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas

Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…

Read More

Molecular profiling and personalized medicine within EURACAN in the SPECTA Arcagen study in comparison to the France Genomic Medicine 2025 Plan in the AURAGEN platform in peritoneal mesotheliomas

Translational Oncology 2026 July [Link] Seddig Momenkhan, Marie Morfouace, Vahan Kepenekian, Olivier Glehen, Laurent Villeneuve, Julio Oliveira, Sabine Tejpar, Sylvie Isaac, Juliette Fontaine, Jean-Yves Blay, Julien Péron, Nazim Benzerdjeb Abstract Peritoneal mesothelioma (PM) is a rare aggressive cancer with limited therapeutic options upon progression. Two genomic profiling initiatives were launched to implement personalized medicine in…

Read More

PIPAC for Malignant Peritoneal Mesothelioma: Current Insights and Future Directions

Digestive Surgery 2026 May 12 [Link] Arianna Castagna, Aphrodite Fotiadou, Ali Ramouz, Preslava Gesheva, Niall Brindl, Wiebke Solass, Andreas Brandl Abstract Malignant peritoneal mesothelioma (MPM) is a rare and aggressive tumour with poor prognosis, often diagnosed late due to nonspecific symptoms. Current standard treatment involves systemic chemotherapy and cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy…

Read More

Prognostic Significance of Inflammatory, Cellular, and Tumor-Specific Biomarkers in Patients With Pleural and Peritoneal Mesothelioma

Clinical Lung Cancer 2026 June [Link] Keval Yerigeri, Manjistha Sengupta, Jingli Zhang, Jeevan Puthiamadathil, Raffit Hassan Abstract Background: Mesothelioma is an aggressive malignancy with poor outcomes, particularly when diagnosed at advanced stages. This study evaluated the prognostic value of tumor-specific biomarkers: soluble mesothelin-related peptide (SMRP), megakaryocyte potentiating factor (MPF) and CA125; inflammatory markers: C-reactive protein…

Read More